ClinicalTrials.gg

Program

regorafenib

Also written as “Regorafenib (Stivarga, BAY73-4506)”, “Regorafenib” and “Regorafenib (BAY73-4506)”.

Its studies are mostly in Colorectal Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Pancreatic Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Furthest: phase 4, since May 24, 201833 company-led studies, 1 open or runningNext primary completion: Apr 27, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer321 open or runningphase 4since May 24, 2018Apr 17, 2008Apr 27, 2028phase 2 · NCT06246643
Sarah Cannon Research Institute10 open or runningphase 2since Apr 21, 2015Apr 21, 2015none ahead

Also a collaborator on its studies: Novartis, Merck, Bristol-Myers Squibb and bayer-healthcare-pharmaceuticals-inc-bayer-schering-pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Apr 17, 2008.

  1. Oct 28, 2013Phase 1 study in NeoplasmsBayer · NCT01973868 · 42 enrolled · United States
  2. Nov 28, 2013Phase 1 study in NeoplasmsBayer · NCT02001909 · 27 enrolled · Germany
  3. Mar 7, 2014Phase 1 study in NeoplasmsBayer · NCT02085148 · 62 enrolled · France, Italy, Spain and more
  4. Apr 4, 2014Phase 1 study in NeoplasmsBayer · NCT02106845 · 42 enrolled · Germany, Hungary
  5. Aug 20, 2014Phase 2 study in Macular DegenerationBayer · NCT02222207 · 52 enrolled · United States, Australia, Austria and more
  6. Mar 20, 2015Phase 1 study in NeoplasmsBayer · NCT02398513 · 18 enrolled · China
  7. Apr 21, 2015Sarah Cannon Research Institute's first study: phase 2 study in Colorectal NeoplasmsNew to Sarah Cannon Research InstituteSarah Cannon Research Institute · NCT02425683 · 24 enrolled · United States
  8. Jun 4, 2015Phase 2 study in Colorectal NeoplasmsBayer · NCT02465502 · 59 enrolled · Brazil
  9. Nov 16, 2017Phase 1 study in Carcinoma, HepatocellularBayer · NCT03347292 · 58 enrolled · United States, Germany
  10. May 24, 2018Phase 4 study in Colorectal NeoplasmsBayer · NCT03564938 · 100 enrolled · India
  11. Mar 25, 2019Phase 2 study in Colorectal NeoplasmsBayer · NCT03890731 · 6 enrolled · United States, Germany, Italy and more
  12. Oct 11, 2019Phase 2 study in Colorectal NeoplasmsBayer · NCT04126733 · 70 enrolled · United States
  13. Jan 4, 20212 phase 2 studiesBayer · NCT04696055, NCT04704154
  14. Jan 14, 2024Phase 2 study in Solid Malignant TumorsBayer · NCT06246643 · 13 enrolled · France, Japan, South Korea and more

Ahead

  1. Apr 27, 2028Primary completion: phase 2 study in Solid Malignant TumorsBayer · NCT06246643

TargetBeta

“Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06246643Solid Malignant Tumors · France, Japan, South Korea and more2Active, not recruitingBayerApr 27, 202813
NCT04704154Squamous Cell Carcinoma of Head and Neck · United States, Belgium, France and more2CompletedBayerMar 9, 2023175
NCT04696055Carcinoma, Hepatocellular · United States, France, Germany and more2CompletedBayerMay 5, 202295
NCT04126733Colorectal Neoplasms · United States2CompletedBayerNov 11, 202070
NCT03890731Colorectal Neoplasms · United States, Germany, Italy and more2CompletedBayerFeb 28, 20236
NCT03564938Colorectal Neoplasms · India4CompletedBayerMar 20, 2023100
NCT03347292Carcinoma, Hepatocellular · United States, Germany1CompletedBayerDec 17, 202058
NCT02465502Colorectal Neoplasms · Brazil2CompletedBayerMay 2, 201759
NCT02425683Colorectal Neoplasms · United States2TerminatedSarah Cannon Research InstituteSep 21, 201724
NCT02398513Neoplasms · China1CompletedBayerNov 201518
NCT02222207Macular Degeneration · United States, Australia, Austria and more2TerminatedBayerMay 201552
NCT02106845Neoplasms · Germany, Hungary1CompletedBayerApr 27, 201542
NCT02085148Neoplasms · France, Italy, Spain and more1CompletedBayerMay 5, 201962
NCT02001909Neoplasms · Germany1CompletedBayerApr 201427
NCT01973868Neoplasms · United States1CompletedBayerJan 31, 201742
NCT01939223Colorectal Neoplasms · United States, Australia, Belgium and more3TerminatedBayerAug 29, 201625
NCT01853046Neoplasms · United States, Canada1CompletedBayerJul 201524
NCT01853319Colorectal Neoplasms · Turkey3CompletedBayerApr 24, 2015100
NCT01774344Carcinoma, Hepatocellular · United States, Argentina, Australia and more3CompletedBayerFeb 29, 2016573
NCT01584830Colorectal Neoplasms · China, Hong Kong, Korea, Republic of and more3CompletedBayerNov 2013204
NCT01339104Neoplasms · United States1CompletedBayerAug 201353
NCT01318265Pharmacokinetics · United States1CompletedBayerJul 201124
NCT01289821Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedBayerMar 201254
NCT01271712Gastrointestinal Stromal Tumors · United States, Austria, Belgium and more3CompletedBayerJan 26, 2012199
NCT01187615Small Cell Lung Carcinoma · United States1TerminatedBayerJun 20129
NCT01103323Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedBayerJul 2011760
NCT01096030Neoplasms · Hong Kong, Singapore1CompletedBayerNov 201233
NCT01117623Neoplasms · United States1CompletedBayerNov 201386
NCT01002378Dietary Fats · United States1CompletedBayerFeb 201024
NCT01003015Carcinoma, Hepatocellular · Germany, Italy, Korea, Republic of and more2CompletedBayerNov 201036
NCT00960258Neoplasms · Japan1CompletedBayerApr 26, 201015
NCT00934882Colorectal Neoplasms · Germany1CompletedBayerApr 201245
NCT00664326Carcinoma, Renal Cell · United States, Finland, France and more2CompletedBayerMay 31, 200949

How it is read

Names in the registry

  • “Regorafenib (Stivarga, BAY73-4506)”, 21 entries
  • “Regorafenib”, 6 entries
  • “Regorafenib (BAY73-4506)”, 4 entries
  • “TAS-102, Regorafenib , Fruquintinib”, 1 entry
  • “Regorafenib, (Stivarga, BAY73-4506)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.